HPV vaccine shows promise for chinese women and girls in large trial

NCT ID NCT03903562

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 study tested a 9-valent HPV vaccine in nearly 2,000 healthy Chinese females aged 9 to 45. The goal was to see if the vaccine triggers a strong immune response and is safe. Participants received three doses, and researchers measured antibody levels over five years, especially in younger participants. The results could support broader use of this vaccine in China to help prevent HPV infections and related cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
9-valent human papillomavirus (HPV) vaccine
What this could lead to
If successful, this could confirm that the 9-valent HPV vaccine is safe and produces a strong immune response in Chinese females aged 9-45, supporting its use to prevent HPV infections and related cancers.
What could go wrong
This is a completed Phase 3 trial, so results are already in. However, the study only measured immune response, not actual prevention of infection or cancer. Long-term effectiveness and real-world impact still need further study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kaihua country Center for Disease Control and Prevention ( Site 0002)

    Quzhou, Zhejiang, 324300, China

  • Shaoxing keqiao center for disease prevention and control ( Site 0001)

    Shaoxing, Zhejiang, 312030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.